Illumina has announced the completion of the spinoff of its oncology-focused healthcare company, GRAIL. The spinoff aimed to divest GRAIL while allowing its breakthrough technology to continue benefiting patients.
Post-separation, GRAIL will operate as an independent public company and will start trading on Nasdaq on June 25 under the ticker symbol "GRAL." Illumina will retain a minority share of 14.5% in GRAIL and has assured continued support for GRAIL’s cancer-fighting efforts through sequencing technology, end-to-end workflows, and support services.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.